Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Filing for WHO Emergency Use Authorisation this month
This robust growth has come despite the raging pandemic for most part of the quarter
Arch Pharma Labs has filed the application
Turnover of API division of ISLL stood at Rs 856.58 crore
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
